Visus Therapeutics Secures $20 Million In Additional Financing Led By New Investor Lsp, With Participation From Sage Partners
Visus Therapeutics Secures $20 Million In Additional Financing Led By New Investor Lsp, With Participation From Sage Partners
08/10/21, 11:04 AM
Location
seattleMoney raised
$20 million
Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced the closing of $20 million in preferred stock financing, led by LSP in Amsterdam, along with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation - JJDC, Inc. and other inside investors in the Company. In conjunction with this financing, John de Koning, Ph.D., a General Partner at LSP, has joined the Company’s Board of Directors.
Company Info
Location
seattle, washington, united states
Additional Info
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter (@VisusTx) and Instagram.
1 Care of the Patient with Presbyopia. American Optometric Association. 2011.
2 Market Scope. Global Presbyopia-Correcting Surgery Market Report. April 2012.